immpact-international

Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence

CD38 expression on myeloma cells is a important issue affecting the early response to the anti-CD38 antibody daratumumab. Nevertheless, elements affecting CD38 expression in untreated a number of myeloma are usually not totally elucidated. On this research, we discovered that CD38 expression was considerably decrease in myeloma sufferers with the translocation t(11;14)-associated immature plasma cell phenotype, and significantly in these expressing B-cell-associated genes comparable to PAX5 and CD79A. CD138, a consultant marker of plasmacytic differentiation, was additionally considerably decrease in these sufferers, suggesting that CD38 expression could also be related to the differentiation and maturation phases of myeloma cells.
Moreover, the BCL2/BCL2L1 ratio, a response marker of the BCL2 inhibitor venetoclax, was considerably larger in sufferers with the immature phenotype expressing B-cell-associated genes. The BCL2/BCL2L1 ratio and CD38 expression had been considerably negatively correlated. We additionally confirmed that sufferers with translocation t(11;14) expressing B-cell-associated genes had been certainly much less delicate to daratumumab-mediated direct cytotoxicity however extremely delicate to venetoclax therapy in ex vivo assays. Furthermore, all-trans-retinoic acid, which boosts CD38 expression and induces cell differentiation in myeloma cells, diminished B-cell marker expression and the BCL2/BCL2L1 ratio in myeloma cell traces, resulting in diminished efficacy of venetoclax.
Venetoclax particularly induces cell dying in myeloma with t(11;14), though why sufferers with translocation t(11;14) present BCL2 dependence is unclear. These outcomes counsel that BCL2 dependence, in addition to CD38 expression, are deeply related to the differentiation and maturation phases of myeloma cells. This research highlights the significance of analyzing t(11;14) and contemplating cell maturity in myeloma therapy methods.
Key phrases: BCL2; CD38; daratumumab; a number of myeloma; venetoclax.

CD142 performs a key position within the carcinogenesis of gastric adenocarcinoma by inhibiting BCL2-dependent autophagy

CD142 is expressed on the floor of a number of malignant tumors and contributes to varied carcinogenesis. Nevertheless, the position of CD142 within the pathogenesis of GAC stays unclear. This research aimed to analyze the position of CD142 in GAC carcinogenesis. Our outcomes confirmed that CD142 expression was considerably elevated in GAC most cancers tissues, particularly in these with vital invasion or metastasis. The invasion and migration of CD142-positive SNU16 cells had been considerably elevated in contrast with these of CD142-negative cells. Furthermore, CD142 overexpression promoted the invasion and migration of SGC083 cells, however CD142 silencing was opposite. As well as, there was a constructive correlation between CD142 expression of most cancers tissues and serum IL-Eight ranges. CD142 overexpression promotes IL-Eight manufacturing in SGC083 cells.
In vivo evaluation confirmed that the implantation of CD142-positive SNU16 cells promoted the expansion of xenograft tumor and the manufacturing of IL-8. Mechanistically, CD142 silencing not solely inhibited the expression of BCL2 and the interplay between BCL2 and Beclin1, but additionally promoted the autophagic response in SGC083. Moreover, CD142 silencing-induced IL-Eight degradation was recovered by therapy of autophagy inhibitor 3-MA. CD142 can inhibit autophagic cell dying and the autophagic degradation of IL-Eight in GAC, which exerts an efficient impact on GAC carcinogenesis.
immpact-international
immpact-international

The Incidence and Remedy Response of Double Expression of MYC and BCL2 in Sufferers with Diffuse Giant B-Cell Lymphoma: A Systematic Evaluate and Meta-Evaluation

MYC/BCL2 protein co-expression (i.e., double expressor) has been proven to be a unfavorable predictor of consequence in diffuse massive B-cell lymphoma (DLBCL). We aimed to determine the incidence of double expressor standing in sufferers with de novo DLBCL and determine the predictive worth of this biomarker on therapy response by way of systematic evaluate and meta-analysis. PubMed and Embase had been looked for research printed by way of December 2019 that reported proportions of double expressor DLBCL. The pooled proportions of MYC and BCL2 expression, each alone and together, had been computed utilizing the inverse variance technique for calculating weights and by the DerSimonian-Laird technique. The pooled odds ratios (ORs) of full remission (CR) fee had been calculated, and meta-regression evaluation was carried out to discover heterogeneity. Forty-one research (7054 sufferers) had been included.
The pooled incidence of double expressor standing in DLBCL was 23% (95% confidence interval [CI], 20-26%), with an adjusted estimate of 31% (95% CI, 27-36%). Neither MYC/BCL2 protein cutoff values, race, imply, or median age of included sufferers, or total research high quality was a big issue of heterogeneity (p ≥ 0.20). Instances with out double expressor standing demonstrated the next likelihood of CR to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy (OR, 2.69; 95% CI, 1.55-4.67). Our outcomes reaffirm the predictive energy of this essential biomarker.
Key phrases: immunohistochemistry; lymphoma; meta-analysis; systematic evaluate.

Computational research on novel pure inhibitors focusing on BCL2

 

Very best lead compounds and candidate medication with inhibitory impact on BCL2 had been screened from ZINC database, which laid a basis for drug growth and compound enchancment of drug therapy for diffuse massive B-cell lymphoma (DLCBL). Identification of potential BCL2 inhibitors by computer-aided digital screening. Libdock was utilized to 17,931 compounds and the highest 20 had been chosen for additional evaluation. Chosen compounds had been carried out absorption, distribution, metabolism, and excretion (ADME) and toxicity prediction. The binding affinity between the chosen ligands and BCL2 was confirmed by Molecular docking.

 

  • The brand new pure compounds, ZINC00000255131 and ZINC00013298233, had been discovered to bind intently with BCL2. Moreover, all of them scored decrease in ames-induced mutagenicity, rodent carcinogenicity, non-developmental toxicity potential, and cytochrome P4502D6 tolerance. Molecular dynamics simulation reveals that the mixtures of ZINC00000255131 and ZINC00013298233 with BCL2 within the pure surroundings are extra secure.
  • Two new compounds, ZINC00000255131 and ZINC00013298233, had been discovered to be potential inhibitors of BCL2. These compounds have been proved to be secure, which is of nice significance for the event and enchancment of DLCBL medication.

 

Assembling BH3-mimic peptide right into a nanocluster to focus on intracellular Bcl2 in the direction of the apoptosis induction of most cancers cell

Bcl-2, an anti-apoptotic protein, is at all times overexpressed in tumor cells to suppress the pro-apoptotic perform of Bax, thereby prolonging the lifetime of tumor. Nevertheless, BH3 proteins may instantly activate Bax by way of antagonizing Bcl-2 to induce apoptosis in response to the stimulation. Thus, mimicking BH3 proteins with a peptide is a possible technique for anti-cancer remedy. Sadly, medical translation of BH3-mimic peptide is hindered by its inefficacious mobile internalization and proteolysis resistance.
Herein, we translated a BH3-mimic peptide right into a peptide-auric spheroidal nanocluster (BH3-AuNp), during which polymeric BH3-Auric precursors [Au1+-S-BH3]n are in-situ self-assembled on the floor of gold nanoparticles by a one-pot synthesis. Expectedly, this technique may enhance the anti-proteolytic potential and cytomembrane penetrability of the BH3 peptide.
Consequently, BH3-AuNp efficiently induced the apoptosis of two most cancers cell traces by an order of magnitude in comparison with BH3. This therapeutic and possible peptide nano-engineering technique will assist peptides overcome the pharmaceutical obstacles, awaken its organic capabilities, and probably revive the analysis about peptide-derived nanomedicine.

Recombinant Human Hydroxymethylglutaryl-CoA lyase, GST, E.coli-200ug

QP6168-ec-200ug 200ug
EUR 760.8

Recombinant Human Hydroxymethylglutaryl-CoA lyase, GST, E.coli-500ug

QP6168-ec-500ug 500ug
EUR 1272

Recombinant Human Hydroxymethylglutaryl-CoA lyase, GST, E.coli-50ug

QP6168-ec-50ug 50ug
EUR 315.6

Human Hydroxymethylglutaryl-CoA lyase, mitochondrial (HMGCL)

1-CSB-EP010563HU
  • EUR 456.00
  • EUR 256.80
  • EUR 1570.80
  • EUR 672.00
  • EUR 1047.60
  • EUR 314.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Hydroxymethylglutaryl-CoA lyase, mitochondrial(HMGCL) expressed in E.coli

2-hydroxyacyl-CoA lyase 1 Antibody

39416-100ul 100ul
EUR 468

Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody

20-abx142080
  • EUR 444.00
  • EUR 727.20
  • EUR 360.00
  • 100 ul
  • 200 ul
  • 50 ul

Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody

20-abx007133
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody

20-abx002856
  • EUR 493.20
  • EUR 710.40
  • 100 ul
  • 200 ul

Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody

abx037986-100ug 100 ug
EUR 469.2

Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody

abx028671-400ul 400 ul
EUR 627.6

Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody

abx028671-80l 80 µl
EUR 343.2

Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody

abx030051-400ul 400 ul
EUR 627.6

Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody

abx030051-80l 80 µl
EUR 343.2

Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody

abx233928-100ug 100 ug
EUR 577.2

Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) Antibody

20-abx322761
  • EUR 526.80
  • EUR 393.60
  • 100 ul
  • 50 ul

anti-2 Hydroxy phytanoyl CoA lyase

YF-PA18196 50 ul
EUR 435.6
Description: Mouse polyclonal to 2 Hydroxy phytanoyl CoA lyase

anti-2 Hydroxy phytanoyl CoA lyase

YF-PA18197 50 ug
EUR 435.6
Description: Mouse polyclonal to 2 Hydroxy phytanoyl CoA lyase

Rhodobacter sphaeroides Modification methylase RsrI (rsrIM)

1-CSB-EP318583RLE
  • EUR 733.20
  • EUR 370.80
  • EUR 2192.40
  • EUR 1126.80
  • EUR 1461.60
  • EUR 476.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Rhodobacter sphaeroides Modification methylase RsrI(rsrIM) expressed in E.coli

2-Hydroxyacyl-CoA Lyase 1 (HACL1) Antibody

20-abx110706
  • EUR 878.40
  • EUR 477.60
  • 150 ul
  • 50 ul

2-Hydroxyacyl-CoA Lyase 1 (HACL1) Antibody

abx145222-100ug 100 ug
EUR 469.2

2-Hydroxyacyl-CoA Lyase 1 (HACL1) Antibody

abx038305-100ug 100 ug
EUR 469.2

2-Hydroxyacyl-CoA Lyase 1 (HACL1) Antibody

abx233746-100ug 100 ug
EUR 610.8

2-Hydroxyacyl-CoA Lyase 1 (HACL1) Antibody

20-abx214192
  • EUR 493.20
  • EUR 360.00
  • 100 ul
  • 50 ul

2-Hydroxyacyl-CoA Lyase 1 (HACL1) Antibody

20-abx214272
  • EUR 493.20
  • EUR 360.00
  • 100 ul
  • 50 ul

Chicken Hydroxymethylglutaryl- CoA lyase, HMGCL ELISA KIT

ELI-27799c 96 Tests
EUR 1113.6

HMGCL 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Human Recombinant Protein

PROTP35914 Regular: 20ug
EUR 380.4
Description: HMGCL Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 323 amino acids (28-325) and having a molecular mass of 34.2kDa.;HMGCL is fused to a 25 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Human Hydroxymethylglutaryl-CoA Lyase, Mitochondrial (HMGCL) ELISA Kit

abx387826-96tests 96 tests
EUR 1093.2

Hmgcl ELISA Kit| Rat Hydroxymethylglutaryl-CoA lyase, mitochond

EF018825 96 Tests
EUR 826.8

Hmgcl ELISA Kit| Mouse Hydroxymethylglutaryl-CoA lyase, mitocho

EF015212 96 Tests
EUR 826.8

Human 2-Hydroxyacyl-CoA Lyase 1 (HACL1) ELISA Kit

abx387730-96tests 96 tests
EUR 1093.2

Human 2- hydroxyacyl- CoA lyase 1, HACL1 ELISA KIT

ELI-27733h 96 Tests
EUR 988.8

Mouse 2- hydroxyacyl- CoA lyase 1, Hacl1 ELISA KIT

ELI-27598m 96 Tests
EUR 1038

Argininosuccinate Lyase (Recombinant)

20-abx073248
  • EUR 4101.60
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

HMGCL Human, 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Human Recombinant Protein, Sf9

PROTP35914-1 Regular: 10ug
EUR 380.4
Description: HMGCL Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 305 amino acids (28-325 a.a.) and having a molecular mass of 32.5kDa (Molecular size on SDS-PAGE will appear at approximately 28-40kDa). HMGCL is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.

3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Like 1 (HMGCLL1) Antibody

abx038037-100ug 100 ug
EUR 469.2

Rat 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase (HMGCL) ELISA Kit

abx391467-96tests 96 tests
EUR 1093.2

Mouse 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase (HMGCL) ELISA Kit

abx389578-96tests 96 tests
EUR 1093.2

3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Like 1 (HMGCLL1) Antibody

20-abx310139
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Selenocysteine Lyase Recombinant Protein

92-018 0.05 mg
EUR 852.9
Description: Selenocysteine Lyase belongs to the class-V pyridoxal-phosphate-dependent aminotransferase family. Selenocysteine Lyase exists as a homodimer in the cytosol. In the brain, Selenocysteine Lyase is as an enzyme that putatively salvages Sec and recycles the selenium for selenoprotein translation. Selenocysteine Lyase catalyzes the decomposition of L-selenocysteine to L-alanine and elemental selenium. Selenocysteine Lyase can be up-regulated In acute glomerulonephritis, it can also be regulated by JUN/AP-1.

Recombinant human Selenocysteine lyase

P2183 100ug Ask for price
Description: Recombinant protein for human Selenocysteine lyase

Cystathionine gamma-lyase, Recombinant

NATE-1144 5mg
EUR 712.8

Cystathionine β-lyase, Recombinant

NATE-1146 100mg
EUR 712.8

3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Like 1 (HMGCLL1) Antibody (HRP)

20-abx310140
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Like 1 (HMGCLL1) Antibody (FITC)

20-abx310141
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Like 1 (HMGCLL1) Antibody (Biotin)

20-abx310142
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Human 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Like 1 (HMGCLL1) ELISA Kit

abx384525-96tests 96 tests
EUR 1093.2

Mouse 3-Hydroxymethyl-3-Methylglutaryl-CoA Lyase Like 1 (HMGCLL1) ELISA Kit

abx388460-96tests 96 tests
EUR 1093.2

Recombinant E.Coli N-Acetylneuraminate Lyase

7-03193 5µg Ask for price

Recombinant E.Coli N-Acetylneuraminate Lyase

7-03194 20µg Ask for price

Recombinant E.Coli N-Acetylneuraminate Lyase

7-03195 1mg Ask for price

Cystathionine Gamma-Lyase Recombinant Protein

92-113 0.05 mg
EUR 651.3
Description: Cystathionine Gamma-Lyase (CTH) belongs to the trans-sulfuration enzymes family. CTH exists as a homotetramer and interacts with CALM in a calcium-dependent manner. CTH breaks down cystathionine into cysteine, ammonia and 2-oxobutanoate. CTH catalyzes the last step in the trans-sulfuration pathway from methionine to cysteine and has broad substrate specificity. Defects in CTH will lead to cystathioninuria, which is an autosomal recessive phenotype characterized by abnormal accumulation of plasma cystathionine.

N-acetylneuraminate Pyruvate Lyase (Recombinant)

20-abx073214
  • EUR 4101.60
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

E.Coli N-Acetylneuraminate Lyase (Recombinant)

20-abx073216
  • EUR 4101.60
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

E.coli Deoxyribodipyrimidine photo-lyase (Recombinant)

20-abx073964
  • EUR 1930.80
  • EUR 393.60
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 2 µg

Recombinant human Cystathionine gamma-lyase

P1802 100ug Ask for price
Description: Recombinant protein for human Cystathionine gamma-lyase

Homocysteine ?,?-Lyase (rHCYase), Active, Recombinant

P1117-200
EUR 510

Recombinant Cystathionine Gamma Lyase (CSE)

4-RPB538Hu01
  • EUR 625.34
  • EUR 290.40
  • EUR 2015.04
  • EUR 751.68
  • EUR 1383.36
  • EUR 494.40
  • EUR 4857.60
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Cystathionine Gamma Lyase expressed in: E.coli

Recombinant Cystathionine Gamma Lyase (CSE)

4-RPB538Mu01
  • EUR 633.95
  • EUR 292.80
  • EUR 2047.30
  • EUR 762.43
  • EUR 1404.86
  • EUR 499.20
  • EUR 4938.24
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Mouse Cystathionine Gamma Lyase expressed in: E.coli

Recombinant Cystathionine Gamma Lyase (CSE)

4-RPB538Ra01
  • EUR 636.10
  • EUR 294.00
  • EUR 2055.36
  • EUR 765.12
  • EUR 1410.24
  • EUR 501.60
  • EUR 4958.40
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Rat Cystathionine Gamma Lyase expressed in: E.coli

Acyl-CoA oxidase, Recombinant

DIA-292 1ku
EUR 324

Methylmalonyl CoA Epimerase (Recombinant)

20-abx073165
  • EUR 4101.60
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

Acyl-CoA synthetase, recombinant

NATE-1682 1ku
EUR 712.8

Recombinant Human Cystathionine γ-Lyase/CTH

CF60-10ug 10ug
EUR 175.2
Description: Supplied as a 0.2 μm filtered solution of 20mM PB,150mM NaCl,20% Glycerol,pH7.4.

Recombinant Human Cystathionine γ-Lyase/CTH

CF60-1mg 1mg
EUR 2739.6
Description: Supplied as a 0.2 μm filtered solution of 20mM PB,150mM NaCl,20% Glycerol,pH7.4.

Recombinant Human Cystathionine γ-Lyase/CTH

CF60-500ug 500ug
EUR 1935.6
Description: Supplied as a 0.2 μm filtered solution of 20mM PB,150mM NaCl,20% Glycerol,pH7.4.

Recombinant Human Cystathionine γ-Lyase/CTH

CF60-50ug 50ug
EUR 406.8
Description: Supplied as a 0.2 μm filtered solution of 20mM PB,150mM NaCl,20% Glycerol,pH7.4.

Recombinant Human N-acetylneuraminate Pyruvate Lyase

7-03232 5µg Ask for price

Recombinant Human N-acetylneuraminate Pyruvate Lyase

7-03233 20µg Ask for price

Recombinant Human N-acetylneuraminate Pyruvate Lyase

7-03234 1mg Ask for price

ATP citrate lyase recombinant monoclonal antibody

A5181 100ul X 3
EUR 714
Description: A recombinant monoclonal antibody from rabbit against human ATP citrate lyase for WB,ELISA

L-Methionine ?-Lyase, Pseudomonas putida recombinant

7848-100
EUR 189.6

L-Methionine ?-Lyase, Pseudomonas putida recombinant

7848-500
EUR 464.4

Hyaluronate Lyase from Streptococcus pyogenes, recombinant

NATE-0346 10mg
EUR 440.4

ADSL Adenylosuccinate Lyase Human Recombinant Protein

PROTP30566 Regular: 20ug
EUR 380.4
Description: ADSL Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 520 amino acids (1-484) and having a molecular mass of 59kDa.;ADSL is fused to a 36 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

ASL Argininosuccinate Lyase Human Recombinant Protein

PROTP04424 Regular: 20ug
EUR 380.4
Description: ASL Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 484 amino acids (1-464) and having a molecular mass of 53.8kDa.;ASL is fused to a 20 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Argininosuccinate Lyase Antibody

DF13850 100ul
EUR 420

Adenylosuccinate Lyase Antibody

DF13918 100ul
EUR 420

Alginate lyase (algL)

1-CSB-EP524422DPX
  • EUR 733.20
  • EUR 370.80
  • EUR 2192.40
  • EUR 1126.80
  • EUR 1461.60
  • EUR 476.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Alginate lyase(algL) expressed in E.coli

Argininosuccinate Lyase antibody

22249-100ul 100ul
EUR 468

Argininosuccinate Lyase antibody

22612-100ul 100ul
EUR 468

Selenocysteine Lyase Antibody

20-abx115419
  • EUR 878.40
  • EUR 477.60
  • 150 ul
  • 50 ul

anti-Adenylosuccinate Lyase

YF-PA10105 50 ug
EUR 435.6
Description: Mouse polyclonal to Adenylosuccinate Lyase

anti-Adenylosuccinate Lyase

YF-PA10106 100 ug
EUR 483.6
Description: Rabbit polyclonal to Adenylosuccinate Lyase

anti-Argininosuccinate Lyase

YF-PA10364 50 ug
EUR 435.6
Description: Mouse polyclonal to Argininosuccinate Lyase

anti-Argininosuccinate Lyase

YF-PA10365 100 ug
EUR 483.6
Description: Rabbit polyclonal to Argininosuccinate Lyase

Recombinant Human Methylmalonyl CoA Epimerase

7-02737 5µg Ask for price

Recombinant Human Methylmalonyl CoA Epimerase

7-02738 20µg Ask for price